DUSP22 and metabolic dysfunction-associated steatohepatitis: The ex vivo gene therapy method using lentivirus-loaded full-length DUSP22 sequences (LV-DUSP22) or shRNA targeting DUSP22 (LV-shDUSP22) was subsequently utilized to disclose the therapeutic potential of DUSP22 for NASH management (Fig. 7a).